Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria
Authors:
- Benedikt LeyBenedikt Ley
- Mohammad Shafiul AlamMAMohammad Shafiul Alam
- Ari Winasti SatyagrahaASAri Winasti Satyagraha
- Ching Swe PhruCPChing Swe Phru
- Dagimawie TadesseDTDagimawie Tadesse
- Tamiru ShibiruTSTamiru Shibiru
- Asrat HailuAHAsrat Hailu
- Mohammad Golam KibriaMKMohammad Golam Kibria
- Mohammad Sharif HossainMohammad Sharif Hossain
Open Access
- 11 May 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 16 (5) , e0010406
Abstract
Primaquine and tafenoquine are the only licensed drugs with activity against Plasmodium vivax hypnozoites but cause haemolysis in patients with glucose–6–phosphate dehydrogenase (G6PD) deficiency. Malaria also causes haemolysis, leading to the replacement of older erythrocytes with low G6PD activity by reticulocytes and young erythrocytes with higher activity. Aim of this study was to assess the impact of acute malaria on G6PD activity. Selected patients with uncomplicated malaria were recruited in Bangladesh (n = 87), Indonesia (n = 75), and Ethiopia (n = 173); G6PD activity was measured at the initial presentation with malaria and a median of 176 days later (range 140 to 998) in the absence of malaria. Among selected participants (deficient participants preferentially enrolled in Bangladesh but not at other sites) G6PD activity fell between malaria and follow up by 79.1% (95%CI: 40.4 to 117.8) in 6 participants classified as deficient (P. vivax or P. falciparum infection. Overall, 66.7% (4/6) severely deficient participants and 87.2% (34/39) with intermediate deficiency had normal activities when presenting with malaria. These findings suggest that G6PD activity rises significantly and at clinically relevant levels during acute malaria. Prospective case-control studies are warranted to confirm the degree to which the predicted population attributable risks of drug induced haemolysis is lower than would be predicted from cross sectional surveys.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1054404)
- Bill and Melinda Gates Foundation (OPP1164105)
- CSL Centenary
- Wellcome Trust (200909)
- Government of Bangladesh
- Governement of Canada
- Governement of Sweden
- Government of UK
This publication has 45 references indexed in Scilit:
- Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiencyBMC Medicine, 2015
- G6PD deficiency: a classic example of pharmacogenetics with on‐going clinical implicationsBritish Journal of Haematology, 2013
- G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD testsMalaria Journal, 2013
- Assessing regression to the mean effects in health care initiativesBMC Medical Research Methodology, 2013
- G6PD Deficiency2013
- The anaemia of Plasmodium vivax malariaMalaria Journal, 2012
- Measurement of Red Cell Lifespan and AgingTransfusion Medicine and Hemotherapy, 2012
- The pathophysiology of vivax malariaTrends in Parasitology, 2009
- Glucose-6-phosphate dehydrogenase deficiencyThe Lancet, 2008
- In vivo lability of glucose-6-phosphate dehydrogenase in GdA- and Gdmediterranean deficiencyJournal of Clinical Investigation, 1968